341 related articles for article (PubMed ID: 30467420)
1. TLR9 agonist enhances radiofrequency ablation-induced CTL responses, leading to the potent inhibition of primary tumor growth and lung metastasis.
Xu A; Zhang L; Yuan J; Babikr F; Freywald A; Chibbar R; Moser M; Zhang W; Zhang B; Fu Z; Xiang J
Cell Mol Immunol; 2019 Oct; 16(10):820-832. PubMed ID: 30467420
[TBL] [Abstract][Full Text] [Related]
2. A new subset of CD103+CD8alpha+ dendritic cells in the small intestine expresses TLR3, TLR7, and TLR9 and induces Th1 response and CTL activity.
Fujimoto K; Karuppuchamy T; Takemura N; Shimohigoshi M; Machida T; Haseda Y; Aoshi T; Ishii KJ; Akira S; Uematsu S
J Immunol; 2011 Jun; 186(11):6287-95. PubMed ID: 21525388
[TBL] [Abstract][Full Text] [Related]
3. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
4. Immune Adjuvant Activity of Pre-Resectional Radiofrequency Ablation Protects against Local and Systemic Recurrence in Aggressive Murine Colorectal Cancer.
Ito F; Ku AW; Bucsek MJ; Muhitch JB; Vardam-Kaur T; Kim M; Fisher DT; Camoriano M; Khoury T; Skitzki JJ; Gollnick SO; Evans SS
PLoS One; 2015; 10(11):e0143370. PubMed ID: 26599402
[TBL] [Abstract][Full Text] [Related]
5. Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells.
Nierkens S; den Brok MH; Garcia Z; Togher S; Wagenaars J; Wassink M; Boon L; Ruers TJ; Figdor CG; Schoenberger SP; Adema GJ; Janssen EM
Cancer Res; 2011 Oct; 71(20):6428-37. PubMed ID: 21788345
[TBL] [Abstract][Full Text] [Related]
6. Enhanced protective immunity derived from dendritic cells with phagocytosis of CD40 ligand transgene-engineered apoptotic tumor cells via increased dendritic cell maturation.
Parameswaran S; Khalil M; Ahmed KA; Sharma RK; Xiang J
Tumori; 2015; 101(6):637-43. PubMed ID: 25983089
[TBL] [Abstract][Full Text] [Related]
7. Distinct roles but cooperative effect of TLR3/9 agonists and PD-1 blockade in converting the immunotolerant microenvironment of irreversible electroporation-ablated tumors.
Babikr F; Wan J; Xu A; Wu Z; Ahmed S; Freywald A; Chibbar R; Wu Y; Moser M; Groot G; Zhang W; Zhang B; Xiang J
Cell Mol Immunol; 2021 Dec; 18(12):2632-2647. PubMed ID: 34782757
[TBL] [Abstract][Full Text] [Related]
8. Combined thermal ablation and liposomal granulocyte-macrophage colony stimulation factor increases immune cell trafficking in a small animal tumor model.
Moussa M; Chowdhury MR; Mwin D; Fatih M; Selveraj G; Abdelmonem A; Farghaly M; Dou Q; Filipczak N; Levchenko T; Torchilin VP; Boussiotis V; Goldberg SN; Ahmed M
PLoS One; 2023; 18(10):e0293141. PubMed ID: 37883367
[TBL] [Abstract][Full Text] [Related]
9. Soluble β-glucan from Grifola frondosa induces tumor regression in synergy with TLR9 agonist via dendritic cell-mediated immunity.
Masuda Y; Nawa D; Nakayama Y; Konishi M; Nanba H
J Leukoc Biol; 2015 Dec; 98(6):1015-25. PubMed ID: 26297795
[TBL] [Abstract][Full Text] [Related]
10. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.
Jackaman C; Bundell CS; Kinnear BF; Smith AM; Filion P; van Hagen D; Robinson BW; Nelson DJ
J Immunol; 2003 Nov; 171(10):5051-63. PubMed ID: 14607902
[TBL] [Abstract][Full Text] [Related]
11. Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8(+) T cells during vaccine immunotherapy.
Takeda Y; Azuma M; Matsumoto M; Seya T
J Exp Clin Cancer Res; 2016 Sep; 35(1):143. PubMed ID: 27619885
[TBL] [Abstract][Full Text] [Related]
12. Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice.
Nierkens S; den Brok MH; Roelofsen T; Wagenaars JA; Figdor CG; Ruers TJ; Adema GJ
PLoS One; 2009 Dec; 4(12):e8368. PubMed ID: 20020049
[TBL] [Abstract][Full Text] [Related]
13. STING agonist-based hydrogel enhances immune activation in synergy with radiofrequency ablation for hepatocellular carcinoma treatment.
Ao F; Li X; Tan Y; Jiang Z; Yang F; Guo J; Zhu Q; Chen Z; Zhou B; Zhang K; Li D
J Control Release; 2024 May; 369():296-308. PubMed ID: 38301925
[TBL] [Abstract][Full Text] [Related]
14. Immune Response After Radiofrequency Ablation and Surgical Resection in Nonsmall Cell Lung Cancer.
Schneider T; Hoffmann H; Dienemann H; Herpel E; Heussel CP; Enk AH; Ring S; Mahnke K
Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):585-592. PubMed ID: 28043482
[TBL] [Abstract][Full Text] [Related]
15. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
Davila E; Celis E
J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
[TBL] [Abstract][Full Text] [Related]
16.
Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
[TBL] [Abstract][Full Text] [Related]
17. Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4
Gallotta M; Assi H; Degagné É; Kannan SK; Coffman RL; Guiducci C
Cancer Res; 2018 Sep; 78(17):4943-4956. PubMed ID: 29945961
[TBL] [Abstract][Full Text] [Related]
18. In vivo immunological antitumor effect of OK-432-stimulated dendritic cell transfer after radiofrequency ablation.
Nakagawa H; Mizukoshi E; Iida N; Terashima T; Kitahara M; Marukawa Y; Kitamura K; Nakamoto Y; Hiroishi K; Imawari M; Kaneko S
Cancer Immunol Immunother; 2014 Apr; 63(4):347-56. PubMed ID: 24384836
[TBL] [Abstract][Full Text] [Related]
19. Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses.
Zhang X; Munegowda MA; Yuan J; Wei Y; Xiang J
J Leukoc Biol; 2010 Aug; 88(2):393-403. PubMed ID: 20466823
[TBL] [Abstract][Full Text] [Related]
20. Co-immunization with L-Myc enhances CD8
Chai D; Zhang Z; Jiang N; Ding J; Qiu D; Shi SY; Wang G; Fang L; Li H; Tian H; Yang J; Zhang Q; Zheng J
Cancer Sci; 2021 Sep; 112(9):3469-3483. PubMed ID: 34157192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
